To Be An Excellent Brand of
Pharmaceutical Intermediates Manufacturer in the world
Breakthroughs in key technologies of drug development and development of new drugs.
2018-4-24 source: unknown clicks: 3 Author: unknown
Since the implementation of the national science and technology major project "major new drug creation", China has broken through a batch of key key technologies, such as antibody and protein preparation, biological macromolecule drug delivery, drug slow controlled release preparation, and two development of Chinese patent medicine, pre clinical safety evaluation and vaccine The technology of R & D and antibody expression has gradually changed from "follow up" to "run" in the world.
(breakthroughs in key technologies for drug discovery and development, major new drug development efforts: Baidu pictures)
In the next 5 to 10 years, the major national science and technology special project of "major new drug creation" will be closely related to the overall goal of accelerating the transformation of medical research and development from the big country to the powerful country, focusing on the serious harm of malignant tumor, neurodegenerative disease, diabetes complication, cardiovascular system disease and so on. Healthy 10 categories (species) major diseases, pioneering and innovative, collaborative research. Now there are more than 200 new drugs in clinical trials, and we are confident that another 30 new drugs will be released during the "13th Five-Year" period. We should further break the monopoly of foreign patent drugs, promote the sharp reduction of foreign patent drugs, and effectively reduce the burden of drugs on patients.
In May 18th, two latest research results on glucagon receptor and glucagon like peptide -1 receptor of our country were published online by the world's top academic journal Nature. These two results provide a direction for the development of new drugs for the treatment of type II diabetes and obesity, and may significantly reduce the medical and economic burden of patients.
Before, Qin Huaijin, the director of the National Health Planning Committee, said: "why Chinese people are expensive, the reason is that 95% of patent medicines and 95% of medical equipment are monopolized by foreign companies." Now, this pattern is gradually being broken. Among them, "major new drug creation" National Science and technology major (special) work can not be done, for 10 years, it is its support, leading the Chinese new drugs from "imitation" to "creation", from "run" to "run" and "run" across.
Independent development and transformation of major drug varieties
"Under the continued cultivation and promotion of the special ten years, 94 new drug certificates have been obtained, including 28 1 new drugs, hand foot and foot disease EV71 vaccine, Sabin polio inactivated vaccine, cecdiamine, ectiinib and apatinib, and more than 200 major varieties, involving 15.3% countries, have been developed and technically transformed. Domestic essential medicines have greatly improved the quality of medicines. " Sang Guowei, chief engineer of special technology and academician of Chinese Academy of engineering.
Sang Guowei introduced the special clinical value oriented, focused on a number of innovative drugs and first drug listing, reformed a number of large variety of drugs, in order to meet the needs of clinical medication, to improve the availability of patients to provide an important support.
"Special focus on major diseases around the industrial chain deployment of R & D chain, new drugs research and development of innovation and quality has been significantly improved." Sang Guowei said that for ten years, the central government has invested 14 billion 300 million yuan in research and development funds in the central government, which has effectively driven the innovation of society and enterprises and achieved direct economic benefits over 160 billion yuan. The number of pharmaceutical enterprises with more than 10 billion revenues increased from 2 to 16 in 2016. Beijing, Tianjin, Bohai, the Yangtze River Delta, the Pearl River Delta and other regions have gradually formed a relatively concentrated and distinctive bio pharmaceutical industry cluster, which has accelerated the regional economic development and industrial transformation and upgrading.
In addition, 16 preparations have been approved to enter the international market since the special implementation, and more than 20 pharmaceutical companies have obtained GMP certification from abroad. The domestic antiepileptic drug lamotrigine controlled-release tablets have occupied more than 60% American market share, and the Chinese patent medicine, Diao Xin Xue Kang capsule and Danshen capsule are listed in the European Union, and a batch of innovative drugs apply for clinical research and listing in the international and domestic fields. China's independently developed Ebola vaccine has successfully completed phase II clinical trials in Sierra Leone, and the experimental drug MIL-77 has successfully cured British female patients.
"In general, the technical aspects have broken through a batch of key technologies, such as antibody and protein preparation, biological macromolecular drug delivery, drug controlled release preparation, and two development of Chinese patent medicine. Pre clinical safety assessment, vaccine development, antibody expression and other technologies have been implemented by 'heel running' to 'running' in the world. Change. " Sang Guowei said.
New drug R & D is to meet clinical needs
"At present, in view of the serious change of the disease spectrum in our country, it is urgent to create a new drug with good curative effect for the chronic and complicated diseases which are high in the population of our country. From the point of view of the clinical needs, it is the only standard to evaluate its value, whether it is a chemical small molecule, or a biotechnological drug, or a traditional Chinese medicine or natural medicine. Special technology vice chief Chen Kaixian said. At present, the development of biotechnology drugs is fast and strong, and has become a new growth point. The proportion of pharmaceutical market share is rising. But chemical medicine is still the main body of the pharmaceutical market, occupying about 80% of the global drug market, and the proportion of the pharmaceutical market in China is up to 50% (about 32% of traditional Chinese medicine and about 18% of biological medicine).
Chen Kaixian believes that compared to chemical small molecule drugs, biotech drugs have a high market value, and their sales are remarkable. Sang Guowei also said that in the world, high throughput